Next Article in Journal
Loop-Mediated Isothermal Amplification (LAMP) for the Diagnosis of Zika Virus: A Review
Next Article in Special Issue
Virus-Like Particles and Nanoparticles for Vaccine Development against HCMV
Previous Article in Journal
Herpesviruses and the Unfolded Protein Response
Previous Article in Special Issue
Simultaneous Immunization with Multivalent Norovirus VLPs Induces Better Protective Immune Responses to Norovirus than Sequential Immunization

Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?

Department of Biological Sciences, Michigan Technological University, Houghton, MI 49931, USA
Current address: Van Andel Research Institute, Grand Rapids, MI 49503, USA
Author to whom correspondence should be addressed.
Viruses 2020, 12(1), 18;
Received: 25 November 2019 / Revised: 15 December 2019 / Accepted: 18 December 2019 / Published: 23 December 2019
(This article belongs to the Special Issue Virus-Like Particle Vaccines)
Human papillomaviruses (HPVs) are the most common sexually transmitted infections worldwide. Ninety percent of infected individuals clear the infection within two years; however, in the remaining 10% of infected individuals, the infection(s) persists and ultimately leads to cancers (anogenital cancers and head and neck cancers) and genital warts. Fortunately, three prophylactic vaccines have been approved to protect against HPV infections. The most recent HPV vaccine, Gardasil-9 (a nonavalent vaccine), protects against seven HPV types associated with ~90% of cervical cancer and against two HPV types associated with ~90% genital warts with little cross-protection against non-vaccine HPV types. The current vaccines are based on virus-like particles (VLPs) derived from the major capsid protein, L1. The L1 protein is not conserved among HPV types. The minor capsid protein, L2, on the other hand, is highly conserved among HPV types and has been an alternative target antigen, for over two decades, to develop a broadly protective HPV vaccine. The L2 protein, unlike the L1, cannot form VLPs and as such, it is less immunogenic. This review summarizes current studies aimed at developing HPV L2 vaccines by multivalently displaying L2 peptides on VLPs derived from bacteriophages and eukaryotic viruses. Recent data show that a monovalent HPV L1 VLP as well as bivalent MS2 VLPs displaying HPV L2 peptides (representing amino acids 17–36 and/or consensus amino acids 69–86) elicit robust broadly protective antibodies against diverse HPV types (6/11/16/18/26/31/33/34/35/39/43/44/45/51/52/53/56/58/59/66/68/73) associated with cancers and genital warts. Thus, VLP-based L2 vaccines look promising and may be favorable, in the near future, over current L1-based HPV vaccines and should be explored further. View Full-Text
Keywords: HPVs; vaccines; virus-like particles (VLPs); minor capsid protein (L2) HPVs; vaccines; virus-like particles (VLPs); minor capsid protein (L2)
Show Figures

Figure 1

MDPI and ACS Style

Yadav, R.; Zhai, L.; Tumban, E. Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today? Viruses 2020, 12, 18.

AMA Style

Yadav R, Zhai L, Tumban E. Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today? Viruses. 2020; 12(1):18.

Chicago/Turabian Style

Yadav, Rashi, Lukai Zhai, and Ebenezer Tumban. 2020. "Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?" Viruses 12, no. 1: 18.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop